Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Replimune Group (NASDAQ: REPL) announced the resignation of Jason Rhodes from its Board of Directors, effective June 3, 2022. Rhodes, a partner at Atlas Venture, served on the board since 2015 and was key during the company's Series A financing. His departure is attributed to increased commitments at Atlas Venture, including a new fund launch. CEO Philip Astley-Sparke expressed gratitude for Rhodes' contributions and highlighted the company's ongoing focus on oncolytic immunotherapies, anticipating significant data releases in the next 12 months.
Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM ET. The event will be held at Marriott Marquis in New York. Founded in 2015, Replimune focuses on innovating tumor-directed oncolytic immunotherapies using its proprietary RPx platform. This platform utilizes an HSV-1 backbone to enhance immune responses against tumors while maintaining a strong safety profile. For more details, visit www.replimune.com.
Replimune Group, a clinical-stage biotechnology firm, presented key updates on its ongoing trials at the 2022 ASCO Annual Meeting from June 3-7, in Chicago.
Highlights include:
- RP1 results from the IGNYTE study, combining RP1 with Opdivo.
- Ongoing trials for RP2 and RP3 programs.
The CERPASS trial aims to evaluate treatment efficacy in advanced cutaneous squamous cell carcinoma, enrolling 180 patients. This study represents a significant step in Replimune's mission to innovate cancer therapies.
Replimune Group, Inc. reported financial results for the fiscal year ending March 31, 2022, indicating a net loss of $118.0 million, up from $80.9 million the previous year. Total research and development expenses reached $79.5 million, an increase from $56.8 million, largely due to expanding clinical trials. The company has a strong cash position of $395.7 million which it believes will fund operations into the second half of 2024. Enrollment in key clinical trials is ongoing, with top line data from significant trials expected in late 2022 and early 2023.
Replimune Group (NASDAQ: REPL) announced promising updates from its Phase 2 IGNYTE trial focusing on RP1, its oncolytic immunotherapy, for melanoma and non-melanoma skin cancers. Initial data reveals that RP1 combined with Opdivo continues to yield deep and durable responses, particularly in anti-PD1 failed patients. New data for RP1 as monotherapy in solid organ transplant recipients shows early clinical activity. The company has announced a broad Phase 2 development plan for RP2/RP3 targeting hard-to-treat tumors, emphasizing its commitment to addressing significant unmet medical needs in oncology.
Replimune Group Inc. (NASDAQ: REPL) will host an investor event on March 30, 2022, at 8:00 AM ET to present updated data from its Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma. New data from the ongoing trial in anti-PD1 failed NMSC will also be shared, alongside findings from the ARTACUS clinical trial involving RP1 as monotherapy for solid organ transplant recipients with skin cancer. The event will be accessible via live webcast on Replimune's website, with a replay available post-event.
Replimune Group, a clinical stage biotechnology company, announced that CEO Philip Astley-Sparke will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET. The event will take place virtually, and a webcast will be accessible on Replimune's website, with a replay available for 90 days post-conference. Replimune specializes in developing tumor-directed oncolytic immunotherapies using its proprietary RPx platform, aiming to enhance cancer treatment through innovative mechanisms.
Replimune Group Inc. (NASDAQ: REPL) reported its financial results for the third fiscal quarter ended December 31, 2021, revealing a net loss of $29.7 million, up from $21.8 million a year ago. Research and development expenses rose to $19.4 million, reflecting heightened clinical activities. The company holds $420.2 million in cash, expected to fund operations until mid-2024. Upcoming milestones include initial data releases from various clinical trials and an investor event in March 2022 to discuss commercial strategies and RP2/3 development plans.
Replimune Group Inc. (NASDAQ: REPL) announced the resignation of Otello Stampacchia, Ph.D., from its Board of Directors effective January 31, 2022. Dr. Stampacchia, a co-leader of Replimune’s seed financing, has decided to focus on his commitments at Omega Funds. CEO Philip Astley-Sparke expressed gratitude for Dr. Stampacchia’s contributions to Replimune's growth from inception to a leader in oncolytic immunotherapies. Replimune aims to innovate cancer treatment through its proprietary RPx platform, enhancing both local and systemic therapeutic effects.
Replimune Group (Nasdaq: REPL) provided a corporate update on January 10, 2022, highlighting the progress of its clinical trials for RP1, RP2, and RP3. The CERPASS trial for RP1 in cutaneous squamous cell carcinoma (CSCC) is on track for enrollment completion mid-year, leading to primary data analysis later. Interim data from the IGNYTE trial, assessing RP1's efficacy in anti-PD1 failed melanoma, is expected by late 2022. Replimune aims to expand RP2 and RP3 trials into diverse cancer types, with detailed development plans to be unveiled in Q1 2022.